Engineered immune cells take on rare Muscle-Weakening disease
Disease control
Recruiting now
This early-stage study tests a new treatment called CD19-BCMA CAR-T for people with refractory generalized myasthenia gravis, a condition where the immune system attacks nerve-muscle connections, causing severe weakness. The therapy uses a patient's own immune cells, modified to …
Phase: PHASE1 • Sponsor: Ting Chang, MD • Aim: Disease control
Last updated May 14, 2026 12:06 UTC